Organisation paid for research Program year 2025 Source: CMS Open Payments

York Hospital

Neither a doctor nor a teaching hospital

Research payments

$153,835

92 payments

Through program year 2025, York Hospital is reported as receiving $153,835 in research payments, across 92 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $6,548 2
2024 Research $20,965 2
2023 Research $8,585 6
2022 Research $4,422 3
2021 Research $5,895 15
2020 Research $38,581 25
2019 Research $68,840 39

Breakdown

Who paid Research payments · program years 2019–2025
  1. Abbott Laboratories $92,398 25 payments
  2. Eli Lilly and Company $41,098 12 payments
  3. Biotronik Inc. $8,936 42 payments
  4. Puma Biotechnology, Inc. $4,100 2 payments
  5. Merck Sharp & Dohme Corporation $3,365 3 payments
  6. Amgen Inc. $2,238 5 payments
  7. TriReme Medical LLC $1,700 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial $38,239 6 payments
  2. Ember-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant VS Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for Er+, Her2- Early Breast Cancer With An Increased Risk of Recurrence $27,535 5 payments
  3. A safety and effectiveness trial for a leadless pacemaker system $19,085 5 payments
  4. AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial $17,205 6 payments
  5. Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker $16,080 5 payments
  6. Bioflow-V $8,936 42 payments
  7. Ember-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant VS Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for Er+ Her2- Early Breast Cancer With An Increased Risk of Recurrence $6,450 2 payments
  8. Emonarcher: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, Her2+ Early Breast Cancer Who Have Completed Adjuvant Her2-Targeted Therapy $4,330 2 payments
  9. A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib $3,900 1 payment
  10. A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy $3,365 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record